2Pfaller MA, jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to Candida albicans: fre- quency of occurrence and antifungal susceptibility in the SCOPE Program[ Jl. Diagn Microbiol Infect Dis, 1998,31:327 - 332.
3Boogaerts M, Winston DJ, Bow J, et al. Intravenous and oral itra- conazole versus intravenous amphotericin B deoxycholate as empir- ical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial thera- py--A randomized, controlled trial [ J ]. Ann intern Med, 2001, 135 :412.
4Pfaller MA, Messer SA, Hollis .R J, et al. Antifungal activities of posaconazo, ravuconazole, and voficonazole compared to those of itraconazole and amphotericin B, against 239 clinical isolates of as- ppergillus spp, and other Filamentous fungi:report from SENTRY antimicrobial surveillance program, 2000 [ J ]. Antimicrob Agents Chemotherapy,2002,46 (4) : 1032 - 1037.
5Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous intraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units[ Jl. Antimicrob Agents Chemother, 1997,41:2714 - 2718.
6Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics [ J ]. J Clin Pharm Ther,2001,26 : 159 - 169.
4Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709.
5Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14.
6Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240.
7Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189.
8Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200.
9Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718.
10Boogaerts M,Winston DJ,Bow EJ,et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy-A randomized,controlled trial[ J]. Ann Intern Med,2001,135 :412.
2Conti G, Costa R, Antonelli M: Non invasive ventilation in immunocompro- mised patients[ J ]. Minerva Anestesiol, 2011,77 (3) : 342.
3Campo M, Lewis RE, Kontoyiannis DP: Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998- 2009 [J]. J Infect 2010,60(5) : 331.
4Luong ML, Filion C, Labbe AC,, et al: Clinical utility and prognostic val- ue of bronchoalveolar lavage galactomarman in patients with hematologic malignancies[J]. Diagn Microbiol Infect Dis,2010,68(2) : 132.
5Lehmbecher T, Frank C, Engels K, et al:Trends in the postmortem epi- demiology of invasive fungal infections at a university hospital [ J ]. J Infect,2010,61 (3) :259.
6Ito JI, Kriengkauykiat J, Dadwal SS, et al:Approaches to the early treat- ment of invasive fungal infection [ J ]. Leuk Lymphoma 2010, 51 ( 9 ) : 1623.
7Warnock DW. Trends in the epidemiology of invasive [ungal infections[J]. Jpn J Med Mycol,2007,48(]) :1.
